CK effective over the long-term

Article

Conductive keratoplasty (CK) is an effective long-term treatment for near-plano presbyopia.

Conductive keratoplasty (CK) is an effective long-term treatment for near-plano presbyopia, according to the results of a study published in the November issue of the Journal of Refractive Surgery.

Jason Stahl, MD from Kansas University Medical Center, Kansas, US evaluated the outcomes of 10 patients treated with unilateral CK, performed using the ViewPoint CK system (Refractec). Nine patients were available for follow-up at three years.

Preoperatively, the average manifest refraction spherical equivalent (MRSE) was -0.17 D and average near uncorrected visual acuity (UCVA) was J10. At three years follow-up, the mean MRSE had decreased to -1.06 D, representing a 0.25 D change from the average MRSE of -1.31 D at one year follow-up. Furthermore, at three years, all subjects had maintained an uncorrected binocular distance visual acuity of 20/20 and near UCVA averaged J3 or better in 78% of subjects.

Dr Stahl concluded that CK can be an effective long-term treatment for presbyopia.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.